Recs

2

Make Money in Global Health-Care Stocks the Easy Way

Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you expect the global health-care industry to thrive as our planet's population grows and ages, the iShares S&P Global Health Care ETF (NYSE: IXJ  ) could save you a lot of trouble. Instead of trying to figure out which companies will perform best, you can use this ETF to invest in lots of them simultaneously.

The basics
ETFs often sport lower expense ratios than their mutual fund cousins. The iShares ETF's expense ratio -- its annual fee -- is a relatively low 0.48%.

This ETF doesn't have the most impressive track record, but its future is what matters most. It outperformed the S&P 500 by a little over the past five years, on average, and underperformed it by less than a percentage point annually over the past 10. As with most investments, of course, we can't expect outstanding performances in every quarter or year. Investors with conviction need to wait for their holdings to deliver.

With an ultra-low turnover rate of 6%, this fund isn't frantically and frequently rejiggering its holdings, as many funds do.

What's in it?
Several of this ETF's components have made strong contributions to its performance so far this year. Abbott Labs (NYSE: ABT  ) , up 18%, sports rising profit margins and strong fundamentals, and plans to split in two soon. Its new pharmaceuticals-only entity will be depending on anti-inflammatory-disease drug Humira for a huge chunk of earnings, which is a bit risky, as it faces competition from Vertex Pharmaceuticals (Nasdaq: VRTX  ) , Pfizer, Incyte (Nasdaq: INCY  ) , and others.

Other companies haven't added as much to the ETF's returns so far in 2011, but could have an effect in the years to come. Amgen (Nasdaq: AMGN  ) , for example, gained only about 1%, but it's embarking on a big share buyback program, aiming to reduce its share count by 10%. That will leave remaining shares more valuable. It's nice, but it's also not the most exciting way to spend $5 billion -- my colleague Brian Orelli suggested that that kind of money could have been spent to buy promising companies such as Dendreon (Nasdaq: DNDN  ) , Aeterna Zentaris (Nasdaq: AEZS  ) , or many others.

The big picture
Demand for global health care isn't going away anytime soon. A well-chosen ETF can grant you instant diversification across any industry or group of companies -- and make investing in and profiting from it that much easier.

Learn about the best dividend ETFs. And if you're looking for some great investments beyond ETFs, consider these 10 stocks for your retirement portfolio.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Longtime Fool contributor Selena Maranjian owns shares of Amgen, but she holds no other position in any company mentioned. Click here to see her holdings and a short bio. The Motley Fool owns shares of Abbott Laboratories and Dendreon. Motley Fool newsletter services have recommended buying shares of Vertex Pharmaceuticals, Pfizer, and Abbott Labs. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 1593798, ~/Articles/ArticleHandler.aspx, 5/25/2012 6:27:56 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 9 hours ago Sponsored by:
DOW 12,529.75 33.60 0.27%
S&P 500 1,320.68 1.82 0.14%
NASD 2,839.38 -10.74 -0.38%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/24/2012 3:59 PM
DNDN $7.22 Down -0.13 -1.77%
Dendreon Corp CAPS Rating: **
INCY $22.66 Up +0.09 +0.40%
Incyte Corp CAPS Rating: **
VRTX $64.09 Up +0.15 +0.23%
Vertex Pharmaceuti… CAPS Rating: ***
ABT $62.42 Up +1.05 +1.71%
Abbott Laboratorie… CAPS Rating: *****
AEZS $0.50 Up +0.03 +5.79%
Aeterna Zentaris,… CAPS Rating: ****
AMGN $69.10 Up +0.72 +1.05%
Amgen, Inc. CAPS Rating: ****

Advertisement